<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Voluntary</title>
	<atom:link href="http://www.tapanray.in/tag/voluntary/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>UCPMP: Vacillating Between ‘The Perfect’ And ‘The Real’ World?</title>
		<link>http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ucpmp-vacillating-between-the-perfect-and-the-real-world</link>
		<comments>http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/#comments</comments>
		<pubDate>Mon, 02 Mar 2020 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Uniform]]></category>
		<category><![CDATA[Vacillating]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[‘The Perfect’]]></category>
		<category><![CDATA[‘The Real’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9896</guid>
		<description><![CDATA[In the ‘perfect world’ one takes ‘perfect decisions’, while in the ‘real world’ one takes a ‘real decision’ &#8211; as the saying goes. In tandem, a raging debate continues on what is ‘perfect’ and what is ‘real’, in the world &#8230; <a href="http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>On The Flip Side of Pharma Industry: A Saga of Perennial Contradictions</title>
		<link>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions</link>
		<comments>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/#comments</comments>
		<pubDate>Mon, 09 Dec 2019 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CEOs]]></category>
		<category><![CDATA[contradiction]]></category>
		<category><![CDATA[contradictions]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[flip]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[perennial]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[side]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vice versa]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9804</guid>
		<description><![CDATA[Awesome contribution in the battle against multiple diseases, is obviously the primary facet of the pharma industry. However, on its flip side, one would witness a saga of numerous contradictions. Some of these exist perennially in well-protected opaque cocoons, regardless &#8230; <a href="http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/on-the-flip-side-of-pharma-industry-a-saga-of-perennial-contradictions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Department of Pharmaceuticals On The Same Page As The Prime Minister?</title>
		<link>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister</link>
		<comments>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/#comments</comments>
		<pubDate>Sun, 14 May 2017 23:56:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AMC]]></category>
		<category><![CDATA[amended]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[malevolent]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Nexus]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[statute]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unholy]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8225</guid>
		<description><![CDATA[“The open secret is that pharmaceutical companies throw all manners of inducements on doctors to prescribe their medicines. The victim of their misdemeanors is the unsuspecting patient. Mr. Modi clearly wants to break this self-serving chain” – highlighted a media &#8230; <a href="http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drugs: A Dangerous Pricing Trend Impacting Patient Access</title>
		<link>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drugs-a-dangerous-pricing-trend-impacting-patient-access</link>
		<comments>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/#comments</comments>
		<pubDate>Mon, 11 Jul 2016 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[dangerous]]></category>
		<category><![CDATA[Daniel]]></category>
		<category><![CDATA[database]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[irresponsible]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[profits]]></category>
		<category><![CDATA[ptent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Stone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[VL]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[Windfall]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7721</guid>
		<description><![CDATA[The upcoming trend of jaw dropping high prices for new patented drugs sends a ‘storm signal’ to many stakeholders, especially for its adverse impact on patient access. Even more intriguing, such high and insane prices are being fixed rather arbitrarily, &#8230; <a href="http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Indian Drug Control World’s Weakest: Pharma Trade Bodies Working At Cross Purposes&#8217;</title>
		<link>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes</link>
		<comments>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/#comments</comments>
		<pubDate>Mon, 25 Apr 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bodies]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[cross-purposes]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Edmund]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safra]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7612</guid>
		<description><![CDATA[&#8220;In the entire world, I think our drug control system probably is the weakest today. It needs to be strengthened,&#8221; said the Secretary of the Department of Pharmaceuticals (DoP) &#8211; V K Subburaj at an event in New-Delhi on April &#8230; <a href="http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Against Pharma Marketing Malpractices: A Gutsy Step</title>
		<link>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=against-pharma-marketing-malpractices-a-gutsy-step</link>
		<comments>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/#comments</comments>
		<pubDate>Mon, 22 Feb 2016 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[58th]]></category>
		<category><![CDATA[BBC]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Clinton]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[conflit]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[dollars for doc]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[follow]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Gutsy]]></category>
		<category><![CDATA[Hilary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharnaceuticals]]></category>
		<category><![CDATA[Physician Payments Sunshine Act]]></category>
		<category><![CDATA[ProPublica]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7447</guid>
		<description><![CDATA[January 7, 2016 edition of ‘The Financial Times (FT)’ reported that responding to escalating pressure on the drug industry, related to its ‘Conflict of Interest’ with the doctors and other related professionals, GlaxoSmithKline (GSK) has decided taking a very unorthodox &#8230; <a href="http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Voluntary Practice Alone of Pharma Marketing Code, Has Never Worked…Anywhere</title>
		<link>http://www.tapanray.in/voluntary-practice-alone-of-pharma-marketing-code-has-never-workedanywhere/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=voluntary-practice-alone-of-pharma-marketing-code-has-never-workedanywhere</link>
		<comments>http://www.tapanray.in/voluntary-practice-alone-of-pharma-marketing-code-has-never-workedanywhere/#comments</comments>
		<pubDate>Mon, 10 Aug 2015 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[anywhere]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[CBDT]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[FOPE]]></category>
		<category><![CDATA[IDMA]]></category>
		<category><![CDATA[IFPMA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[Marketing Code]]></category>
		<category><![CDATA[never worked]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[SPIC]]></category>
		<category><![CDATA[sunshine act]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6923</guid>
		<description><![CDATA[Since the last three and a half decades, ‘Code of Pharmaceutical Marketing Practices’, prepared by various global pharma trade associations and most of the large global pharma companies individually, have come into existence for strictest voluntary adherence. These are being relentlessly &#8230; <a href="http://www.tapanray.in/voluntary-practice-alone-of-pharma-marketing-code-has-never-workedanywhere/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/voluntary-practice-alone-of-pharma-marketing-code-has-never-workedanywhere/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Aggressive New Drug Pricing Trend: What It Means To India?</title>
		<link>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-aggressive-new-drug-pricing-trend-what-it-means-to-india</link>
		<comments>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/#comments</comments>
		<pubDate>Mon, 27 Oct 2014 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[aggressive]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Express]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Harmony]]></category>
		<category><![CDATA[HCV. Sovaldi]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Script]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[VL]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6134</guid>
		<description><![CDATA[A new class and an aggressive drug-pricing trend is now evolving in the global pharmaceutical industry, exerting huge financial pressure on the patients and payers, including governments, especially, in the developed nations of the world. Another aspect of this issue &#8230; <a href="http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gilead: Caught Between A Rock And A Hard Place In India</title>
		<link>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gilead-caught-between-a-rock-and-a-hard-place-in-india</link>
		<comments>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/#comments</comments>
		<pubDate>Mon, 22 Sep 2014 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alliance]]></category>
		<category><![CDATA[Between. Rock]]></category>
		<category><![CDATA[Cadila Healthcare]]></category>
		<category><![CDATA[Caught]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[Hetero labs and Sequent Scientific]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO. Indian]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[monopolies]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Place]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Strides Arcolab]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tenofovir]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6001</guid>
		<description><![CDATA[I had mentioned in my blog post of August 4, 2014, titled “Hepatitis C: A Silent, Deadly Disease: Treatment beyond reach of Most Indians” that in line with Gilead’s past approach to its HIV medicines, the company would offer to &#8230; <a href="http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ethical Pharmaceutical Marketing Practices: &#8216;Self-Regulation&#8217;&#8230;&#8217;Voluntary Physician Payments Disclosure&#8217;&#8230;What&#8217;s next?</title>
		<link>http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next</link>
		<comments>http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/#comments</comments>
		<pubDate>Mon, 09 Nov 2009 00:30:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=730</guid>
		<description><![CDATA[Over a period of time, many stakeholders of the pharmaceutical industry and the public at large have been raising the issue of physicians being influenced in their prescription decisions by various types of payments made to them by the pharmaceutical &#8230; <a href="http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ethical-pharmaceutical-marketing-practices-self-regulation-voluntary-physician-payments-disclosure-whats-next/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
